Literature DB >> 26135869

Comparison of Three Commercial Molecular Assays for Detection of Rifampin and Isoniazid Resistance among Mycobacterium tuberculosis Isolates in a High-HIV-Prevalence Setting.

K Strydom1, F Ismail2, M M Z Matabane2, O Onwuegbuna3, S V Omar4, N Ismail5.   

Abstract

In a head-to-head comparison of the MTBDRplus version 2.0 (Hain Lifescience), the Xpert MTB/RIF (Cepheid), and the Anyplex MTB/NTM (Seegene) assays, we demonstrated equal sensitivity (59/61; 96.7%) and specificity (53/54; 98.1%) for detecting rifampin resistance with further analysis of discordances. The Xpert assay does not detect isoniazid resistance while the Anyplex assay showed high false positivity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26135869      PMCID： PMC4540900          DOI： 10.1128/JCM.01691-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  20 in total

1.  Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay.

Authors:  K Hirano; C Abe; M Takahashi
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

2.  Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.

Authors:  Paolo Miotto; Federica Piana; Valeria Penati; Filippo Canducci; Giovanni Battista Migliori; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

3.  The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population.

Authors:  Pablo Bifani; Barun Mathema; Natalia Kurepina; Elena Shashkina; Julie Bertout; Anne Sophie Blanchis; Soraya Moghazeh; Jeffrey Driscoll; Brigitte Gicquel; Richard Frothingham; Barry N Kreiswirth
Journal:  J Infect Dis       Date:  2008-07-01       Impact factor: 5.226

4.  Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.

Authors:  B Yang; H Koga; H Ohno; K Ogawa; M Fukuda; Y Hirakata; S Maesaki; K Tomono; T Tashiro; S Kohno
Journal:  J Antimicrob Chemother       Date:  1998-11       Impact factor: 5.790

5.  Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis.

Authors:  Syed Beenish Rufai; Parveen Kumar; Amit Singh; Suneel Prajapati; Veena Balooni; Sarman Singh
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

6.  Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas.

Authors:  V Kapur; L L Li; S Iordanescu; M R Hamrick; A Wanger; B N Kreiswirth; J M Musser
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

Review 7.  Mechanisms of drug resistance in Mycobacterium tuberculosis.

Authors:  Y Zhang; W W Yew
Journal:  Int J Tuberc Lung Dis       Date:  2009-11       Impact factor: 2.373

8.  Comparison of performance of two DNA line probe assays for rapid detection of multidrug-resistant isolates of Mycobacterium tuberculosis.

Authors:  Suhail Ahmad; Noura M Al-Mutairi; Eiman Mokaddas
Journal:  Indian J Exp Biol       Date:  2009-06       Impact factor: 0.818

9.  Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

10.  Tuberculosis drug resistance mutation database.

Authors:  Andreas Sandgren; Michael Strong; Preetika Muthukrishnan; Brian K Weiner; George M Church; Megan B Murray
Journal:  PLoS Med       Date:  2009-02-10       Impact factor: 11.069
View more
  4 in total

1.  MTBDRplus for the rapid diagnosis of ocular tuberculosis and screening of drug resistance.

Authors:  K Sharma; A Gupta; M Sharma; A Sharma; R Singh; K Aggarwal; R Bansal; A Thakur; S Prakash; V Gupta
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

Review 2.  Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.

Authors:  Samantha Pillay; Karen R Steingart; Geraint R Davies; Marty Chaplin; Margaretha De Vos; Samuel G Schumacher; Rob Warren; Grant Theron
Journal:  Cochrane Database Syst Rev       Date:  2022-05-18

3.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

Review 4.  Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis.

Authors:  Kaican Zong; Chen Luo; Hui Zhou; Yangzhi Jiang; Shiying Li
Journal:  BMC Microbiol       Date:  2019-08-05       Impact factor: 3.605
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.